# Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening

> **NCT04267081** · PHASE2 · COMPLETED · sponsor: **Helsinki University Central Hospital** · enrollment: 104 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04267081
- **Lead sponsor:** Helsinki University Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-12
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2024-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04267081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04267081, "Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT04267081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*